121 related articles for article (PubMed ID: 34333937)
21. Serum microRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma: a meta-analysis.
Chen Y; Dong B; Huang L; Huang H
Bosn J Basic Med Sci; 2022 Oct; 22(6):862-871. PubMed ID: 35678022
[TBL] [Abstract][Full Text] [Related]
22. Expressions of CK-19, NF-kappaB, E-cadherin, beta-catenin and EGFR as diagnostic and prognostic markers by immunohistochemical analysis in thyroid carcinoma.
Sethi K; Sarkar S; Das S; Rajput S; Mazumder A; Roy B; Patra S; Mohanty B; El-Naggar AK; Mandal M
J Exp Ther Oncol; 2011; 9(3):187-99. PubMed ID: 22070050
[TBL] [Abstract][Full Text] [Related]
23. The cytological diagnosis of a 'benign thyroid lesion': is it a real safe diagnosis for the patient?
Rossi ED; Bizzarro T; Fadda G; Pontecorvi A; Bernet V; Nassar A
Cytopathology; 2016 Jun; 27(3):168-75. PubMed ID: 26388423
[TBL] [Abstract][Full Text] [Related]
24. Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.
Li M; Song Q; Li H; Lou Y; Wang L
PLoS One; 2015; 10(7):e0132403. PubMed ID: 26168287
[TBL] [Abstract][Full Text] [Related]
25. [Differential protein expressions in papillary thyroid carcinoma patients with or without Hashimoto's thyroiditis].
Lu HZ; Zhang N; Liu W; Zhu XY; Qi D; Wang Y; Liu XY; Li ZJ
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):463-468. PubMed ID: 32575941
[No Abstract] [Full Text] [Related]
26. Diagnostic utility of CD56 immunohistochemistry in papillary carcinoma of the thyroid.
El Demellawy D; Nasr AL; Babay S; Alowami S
Pathol Res Pract; 2009; 205(5):303-9. PubMed ID: 19153015
[TBL] [Abstract][Full Text] [Related]
27. Papillary thyroid tumors: Diagnostic value of CD56 and Cytokeratin 19.
Zehani A; Bani A; Chelly I; Rejaibi S; Besbes G; Haouet S; Kchir N
Tunis Med; 2018 Feb; 96(2):113-121. PubMed ID: 30324976
[TBL] [Abstract][Full Text] [Related]
28. Combined staining for immunohistochemical markers in the diagnosis of papillary thyroid carcinoma: improvement in the sensitivity or specificity?
Wu G; Wang J; Zhou Z; Li T; Tang F
J Int Med Res; 2013 Aug; 41(4):975-83. PubMed ID: 23857157
[TBL] [Abstract][Full Text] [Related]
29. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma.
Bychkov A; Sampatanukul P; Shuangshoti S; Keelawat S
Pathology; 2016 Aug; 48(5):425-33. PubMed ID: 27311870
[TBL] [Abstract][Full Text] [Related]
30. A meta-analysis of circulating microRNAs in the diagnosis of papillary thyroid carcinoma.
Liu Y; Geng H; Liu X; Cao M; Zhang X
PLoS One; 2021; 16(5):e0251676. PubMed ID: 34019567
[TBL] [Abstract][Full Text] [Related]
31. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid.
El Demellawy D; Nasr A; Alowami S
Diagn Pathol; 2008 Feb; 3():5. PubMed ID: 18254952
[TBL] [Abstract][Full Text] [Related]
32. Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.
Ma H; Yan J; Zhang C; Qin S; Qin L; Liu L; Wang X; Li N
Int J Clin Exp Pathol; 2014; 7(11):7999-8007. PubMed ID: 25550843
[TBL] [Abstract][Full Text] [Related]
33. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility.
Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V
Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197
[TBL] [Abstract][Full Text] [Related]
34. DNA Methylation-Based Method to Differentiate Malignant from Benign Thyroid Lesions.
Barros-Filho MC; Dos Reis MB; Beltrami CM; de Mello JBH; Marchi FA; Kuasne H; Drigo SA; de Andrade VP; Saieg MA; Pinto CAL; Kowalski LP; Rogatto SR
Thyroid; 2019 Sep; 29(9):1244-1254. PubMed ID: 31328658
[No Abstract] [Full Text] [Related]
35. The diagnostic utility of cytokeratin 19 in differentiating malignant from benign thyroid lesions.
Wa Kammal WS; Yahaya A; Shah SA; Abdullah Suhaimi SN; Mahasin M; Mustangin M; Md Isa N
Malays J Pathol; 2019 Dec; 41(3):293-301. PubMed ID: 31901914
[TBL] [Abstract][Full Text] [Related]
36. The clinicopathological significance of Ki67 in papillary thyroid carcinoma: a suitable indicator?
Tang J; Gui C; Qiu S; Wang M
World J Surg Oncol; 2018 May; 16(1):100. PubMed ID: 29855303
[TBL] [Abstract][Full Text] [Related]
37. Mean platelet volume could be a possible biomarker for papillary thyroid carcinomas.
Baldane S; Ipekci SH; Sozen M; Kebapcilar L
Asian Pac J Cancer Prev; 2015; 16(7):2671-4. PubMed ID: 25854344
[TBL] [Abstract][Full Text] [Related]
38. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-451 as a prognostic marker for diagnosis and lymph node metastasis of papillary thyroid carcinoma.
Zhang M; Wu W; Gao M; Fei Z
Cancer Biomark; 2017 Jul; 19(4):437-445. PubMed ID: 28582849
[TBL] [Abstract][Full Text] [Related]
40. Lymph node fine-needle aspiration washout thyroglobulin in papillary thyroid cancer: Diagnostic value and the effect of thyroglobulin antibodies.
Konca Degertekin C; Yalcin MM; Cerit T; Ozkan C; Kalan I; Iyidir OT; Altinova AE; Akturk M; Toruner F; Akin M; Cakir N
Endocr Res; 2016 Nov; 41(4):281-289. PubMed ID: 26905960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
